Shares of Personalis (NASDAQ:PSNL) tumbled 11.6% on Monday, even after the genomic testing firm received a $16.25 per share acquisition offer from Tempus AI (NASDAQ:TEM). The decline reflects investor unease over the deal's structure and the relatively slim premium, which stood at just 5.6% above Friday's closing price of $15.39. Tempus AI also saw its stock fall 6.2%, while the Nasdaq Composite edged up 0.35% to 25,608.79 as U.S. markets remained open.
By 1:41 p.m. EDT, Personalis shares were trading at $13.61, representing a 16.2% discount to the headline offer price. This gap underscores the market's skepticism about the deal's completion and valuation. The transaction values Personalis at an enterprise value of approximately $1.5 billion, adjusted for Tempus's existing shareholding in the company.
The bid's premium is notably modest. The headline offer of $16.25 is only 5.6% higher than Friday's close, while the stated 28% premium is calculated against an unaffected volume-weighted average price (VWAP) of around $12.70. Roughly 76% of that increase had already been priced into Personalis shares by Friday's close, suggesting that much of the deal's expected value was already reflected in the stock price.
The deal structure adds complexity. Tempus can choose to pay up to half of the consideration in cash, with the remainder settled in Tempus shares at a variable exchange ratio, capped at a maximum of 0.3356 Tempus shares per Personalis share. This cap implies a value of $16.25 if Tempus stock trades at $48.42. At 1:41 p.m. EDT, Tempus shares were at $49.20, just 1.6% above that threshold. If Tempus's stock price falls below $48.42, the stock portion of the payment would be worth less than the headline figure. For example, at $46 per Tempus share, the capped all-stock payment would be approximately $15.44. Should Tempus stock drop below $46, Personalis has the right to terminate the agreement.
Guggenheim analyst Subbu Nambi linked the decline in Personalis shares to the stock-based deal structure, noting that Personalis shareholders are skeptical about the potential benefits of the acquisition. Tempus announced the acquisition of NeXT Personal, a blood-based test for detecting minimal residual disease (MRD), a market Tempus estimates at $20 billion. The two companies have collaborated since November 2023, and roughly 10% of Tempus's sales team currently markets NeXT Personal. Tempus views expanding distribution as a key growth opportunity.
Personalis reported estimated second-quarter revenue of $22.4 million and clinical volume of 10,384 tests, a 33% increase from the previous quarter. Tempus CEO Eric Lefkofsky said the company aimed to "quickly turn into a really healthy business" in terms of gross profit and margins, but held off on further details.
The transaction has received approval from both boards and is expected to close in late 2026 or early 2027, pending shareholder and regulatory clearance. However, risks remain, including further weakness in Tempus shares, a failed shareholder vote, or regulatory delays. Challenges related to reimbursement or integration could also undermine the deal's financial benefits. The spread is now closely tied to Tempus's stock price rather than the $16.25 offer, with key thresholds at $48.42 for the cap and $46 for termination risk.
